During cancer progression, the deregulation of ECM contributes to EMT, a process that involves loss of epithelial cell–cell junction, which is associated with the decreased expression of epithelial markers like E-cadherin and the increased expression of mesenchymal markers (viz., fibronectin, vimentin, fibronectin, N-Cadherin) and MMPs (MMP-2, MMP-3, MMP-9) [69]. Here, MMP2 is linked to cancer.